VSee Health Reports 2025 Financial Results: Revenue Grows 40% Year-over-Year with a Strong Year End Balance Sheet
Rhea-AI Summary
VSee Health (Nasdaq:VSEE) reported full-year 2025 results with revenue up 40% to $14,618,184 and a materially stronger balance sheet after debt-to-equity conversions. Cash and equivalents rose to $5,266,286 at year-end. The company said operating expenses fell sharply and management expects continued contract-driven growth in 2026.
The company noted multi-year institutional contracts (including a previously announced $10 million per year deal), FedRAMP High approval for VSee Labs, and ongoing telehealth rollouts across multiple states.
Positive
- Revenue +40% to $14,618,184 in 2025
- Cash and equivalents increased to $5,266,286 from $326,115
- Operating expenses declined by 76%
- Signed large multi-year institutional contracts including a $10 million/year deal
- Achieved FedRAMP High status for VSee Labs
Negative
- Majority of 2025 growth concentrated in the second half, creating timing risk for revenue recognition
- Extremely high legal, accounting, and integration expenses tied to the IPO in 2024–2025
News Market Reaction – VSEE
In the Apr 2 session, VSEE declined 5.91%, reflecting a notable negative market reaction. Argus tracked a peak move of +22.1% during that session. Argus tracked a trough of -12.5% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 17 | Q2 2025 results | Positive | -7.9% | Reported 98% YoY revenue growth and better cash use for H1 2025. |
| Nov 15 | Q3 2024 results | Positive | +2.3% | Q3 2024 revenue up 131% YoY despite large goodwill impairment-driven net loss. |
| Sep 23 | Q2 2024 update | Positive | +13.8% | De‑SPAC business update with 33% YoY Q2 revenue growth and new partnerships. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings releases have often been positive on growth but produced mixed price reactions, with two prior gains and one notable selloff.
Over recent earnings cycles, VSEE highlighted strong revenue growth and margin improvements, including Q2 2024 gains and a later Q3 2024 revenue surge alongside a large impairment-driven net loss. By Q2 2025, revenue nearly doubled year-over-year and cash use improved. Today’s full-year 2025 results with 40% revenue growth and higher cash build on this trajectory of scaling telehealth operations while working to narrow losses and strengthen the balance sheet.
Key Terms
telehealth medical
integrated health networks medical
fedramp high regulatory
hhs regulatory
10-k regulatory
management's discussion and analysis financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, CA / ACCESS Newswire / April 1, 2026 / VSee Health, Inc. (Nasdaq:VSEE), a leader in AI-powered telehealth technology and high-acuity virtual care solutions, today reported its financial and operational results for the full year ended December 31, 2025. The Company delivered strong top-line growth and meaningful margin improvement while significantly narrowing its net loss.
Key Financial Highlights (Year-over-Year Comparisons)
Revenue increased
40% to$14,618,184 in 2025 from$10,421,352 in 2024
Gross margin rose
2% to$7,355,965 from$7,177,580
Operating expenses declined sharply by
76%
The Company strengthened its balance sheet through multiple debt to equity conversions
Cash and liquidity: Cash and cash equivalents increased to
$5,266,286 at December 31, 2025, from$326,115 at December 31, 2024
Key Business Highlights
During 2025 VSee Health focused on reducing public expenses associated with the IPO, and growth in its telehealth clinical services group.
The company derived its
VSee Health continues to service government accounts such as NASA. In 2025 VSee Labs Inc was nominated and approved for Fedramp High status with the Federal Government as a technology partner. This was achieved through its HHS (Health and Human Services) contract awarded during 2024 and into 2025. VSee continues to pursue several government healthcare related projects in 2026.
VSee Health experienced extremely high legal, accounting, and integration expenses associated with the IPO process in 2024 and 2025. The executive team worked diligently with the Board of Directors to streamline all operations during 2025. VSee believes it can continue to lower its operating costs while growing revenue during 2026.
Outlook and Strategic Position
VSee Health enters 2026 with a fully integrated digital-to-physical care platform, scalable AI telehealth infrastructure, and proven high-acuity clinical delivery. The Company continues to target the rapidly growing hybrid care market while focusing on operational efficiencies, contract renewals, and new enterprise wins. Management remains committed to achieving sustainable profitability and delivering long-term shareholder value.
Investors and interested parties are encouraged to review the complete 10-K filing, which includes detailed financial statements, Management's Discussion and Analysis, risk factors, and business overview, at www.sec.gov or VSeeHealth.com/investors.
About VSee Health, Inc. (Nasdaq: VSEE)
VSee Health is a leader in AI-powered telehealth technology, providing configurable virtual care solutions-including secure video, remote monitoring, AI-enhanced workflows, and seamless EHR integrations-for health systems, government agencies, and large enterprises. Through its iDoc subsidiary, the Company also delivers high-acuity specialty physician services in neurology, tele-radiology, cardiac, and critical care via telehealth.
Forward-Looking Statements
Matters discussed in this news release that are not statements of historical or current facts, including but not limited to those relating to VSee Health's ability to improve healthcare access and provider efficiencies, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause performance or achievements to be materially different from historical results or from any future performance or achievements expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. More information on risk factors relating to VSee Health and its technology and billing services is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of VSee Health's periodic and current filings with the SEC, which are also made available on VSee Health's website at www.vseehealth.com. Forward-looking statements speak only as of the date they are made, and VSee Health undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.
Contact:
VSee Health
Anne Chang
media@vsee.com
VSee Investor Contact:
Milton Chen
VSee Health
investor@vsee.com
SOURCE: VSee Health, Inc.
View the original press release on ACCESS Newswire